Ratings Boule Diagnostics AB

Equities

BOUL

SE0011231158

Market Closed - Nasdaq Stockholm Other stock markets 11:29:47 2024-05-24 am EDT			5-day change	1st Jan Change
10.1 ^SEK	+0.50%		-0.98%	-9.98%

May. 08	Boule Diagnostics AB Appoints Rikke Rytter as Director	CI
May. 07	Transcript : Boule Diagnostics AB, Q1 2024 Earnings Call, May 07, 2024

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

With a P/E ratio at 11.09 for the current year and 8.93 for next year, earnings multiples are highly attractive compared with competitors.
The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
The company appears to be poorly valued given its net asset value.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.

Weaknesses

Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
BOULE DIAGNOSTICS AB	-9.98%	36.84M	B-
THERMO FISHER SCIENTIFIC	+10.03%	223B	B
DANAHER CORPORATION	+13.59%	195B	B-
INTUITIVE SURGICAL, INC.	+20.01%	144B	B-
BOSTON SCIENTIFIC CORPORATION	+30.83%	111B	A-
SIEMENS HEALTHINEERS AG	+2.05%	65.01B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.38%	53.02B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+3.96%	50.45B	B+
AGILENT TECHNOLOGIES, INC.	+8.37%	44.15B	A
GE HEALTHCARE TECHNOLOGIES INC.	+3.27%	36.45B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes